www.fdanews.com/articles/150190-genzyme-presents-second-phase-iii-study-of-once-daily-oral-aubagio

Genzyme Presents Second Phase III Study of Once-daily Oral Aubagio

October 12, 2012

Genzyme announced that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Yahoo! Finanace